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Conclusions: A linac-based coplanar VMAT technique for HA-
PCI was developed, providing high quality treatment plans 
meeting all the study objectives.  
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Purpose/Objective: The complexity of IMRT techniques 
makes patient-specific verification a prerequisite, and the 
use of Portal Dosimetry has practical advantages. 
The purpose is to validate the Portal Dosimetry system 
against the standard QA system (diode array 2D), in order to 
use it for routine QA. 
Materials and Methods: 
-2D diode matrix Sun Nuclear MapCHECK2™ (standard check 
device)  
-Linac Varian Clinac™ 2100C/D with portal vision type AS500™ 
(PV) 
-Philips Pinnacle™ Treatment Planning system version 9.8 
(TPS) 
-Sun Nuclear™ software: SNC Patient™, EPIDose™, and 3DVH™. 
The EPIDose™ was commissioned for dosimetric measures 
(two models were made for gray level to dose conversion, 
one for 100cm and other for 130cm SDD). The 130cm model 
has greater resolution and allows higher dose rate (DR), but 
with smaller field size. From EPIDose™ or MapCHECK2™ data, 
SNC Patient™ generates a 'Perturbated dose matrix', the 3D 
dose distribution from the measures. 3DVH™ compares it with 
the calculated dose matrix from the TPS. It’s a volumetric QA 
system. 
38 QA measures were made in both devices for 22 different 
treatment plans (12 prostate and 26 Head and Neck (H&N) 
cases). All passed the standard MapCHECK2™ test. 
The validation process analyzes: 
- Dose coincidence with Portal Dosimetry and 3DVH™ for the 
whole body (see figure below), targets and organs at risk, 
using the global gamma criterion (3%-3mm) with matching 
rate of 95%. 
- Difference of these values with those of MapCHECK2™ array. 
- Portal Dosimetry passing rates (% of plans ok)  
- Concordance of the two EPIDose™ models used (distance 
100 cm and 130 cm). 
- Reproducibility of the measures. 
 
 
 
 
Results: 
 
- Average % passing points (1) are all over 95% with Portal 
Dosimetry. 
- Passing rate differences in 3DVHs (2) shows greater 
coincidence with TPS for MapCHECK2™ than for EPIDose™ 
(negative values).  
- In 71 % of cases the plan was ok in both devices (3) (100% 
using matching rate of 90%). The results are ≈30% better for 
prostate. 
- Concordance: 14 cases. Mean difference: 0.27%. SD: 2.65% 
- Reproducibility: 6 Cases: difference range: 0.2% - 4.3% 
 
Conclusions: The portal vision system together with EPIDose™ 
and 3DVH™ can be used for IMRT QA in prostate cases. 
Further modeling effort should be done with H&N. 
The measure time is greater with EPIDose™ due to the lower 
dose rate. But it could be faster if the number of treatments 
is low, because of the set-up time. 
The lower EPIDose™ passing rates are due to its bigger spatial 
resolution (lower pixel size): It is more restrictive than 
MapCHECK2™ and can detect smaller hot/cold spots. 
It has the inconvenient of not being able to take into account 
the MU/dose equivalence. However, this way it is a 
redundant check of the MU/Dose equivalence (measures 
closer to real treatment conditions). 
The 130cm distance model shows better results. Greater 
differences have been detected on the edge of fields because 
of the greater ratio border/area for this SSD. 
   
